Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Puma Biotechnology reports revenue growth and strategic advancements in oncology

Puma Biotechnology's Q4 2022 performance reflects revenue growth, cost reductions, and a focus on improving NERLYNX sales.
The company faces challenges in addressing financial losses, FDA trial requirements, and optimizing commercial strategies.
Opportunities in advancing clinical programs, FDA discussions, and market expansion present avenues for future growth and innovation.
Overall, Puma's strategic focus on revenue enhancement, cost control, and innovative treatments positions them for continued progress in the oncology market.

Puma Biotechnology reports solid Q1 earnings, eyes oncology expansion

Puma Biotechnology's Q1 2023 performance driven by strong NERLYNX sales and revenue growth.
Focus on in-licensing alisertib and optimizing expenses for sustained profitability.
Challenges include competition, patent issues, and trial enrollment hurdles.
Opportunities lie in expanding alisertib's indications and in-licensing assets for growth.

Puma Biotechnology reports revenue growth and advances in clinical trials

Puma Biotechnology's Q2 2023 performance showcased revenue growth driven by NERLYNX sales and promising results from alisertib trials. Despite challenges in NERLYNX prescriptions and FDA expectations, strategic initiatives aim to boost sales and advance clinical development. Opportunities in commercial strategies and clinical trials present avenues for future growth.

Puma Biotechnology reports solid Q3 earnings amidst sales challenges

Puma Biotechnology reported solid financial performance in Q3 2023 despite challenges in NERLYNX sales.
The company's focus on improving sales, pursuing clinical trials, and reducing expenses positions it for future growth.
Opportunities lie in enhancing NERLYNX sales, diversifying the product portfolio, and achieving clinical milestones.
Navigating challenges in sales and portfolio diversification while capitalizing on opportunities will be key for Puma's success.

Puma Biotechnology reports stable Q4 earnings amidst prescription challenges

Puma Biotechnology's Q4 2023 performance reflects solid revenue figures and a focus on profitability despite prescription declines.
The company's strengths lie in its innovative trials, commercial strategies, and optimistic revenue projections for the future.
Challenges include prescription decreases and inventory impacts, while opportunities exist in diversification, engagement enhancement, and market differentiation.

Puma Biotechnology reports revenue growth and strategic expansion plans

Puma Biotechnology's Q1 2024 performance reflects revenue growth and strategic initiatives to drive sales and enhance profitability.
While facing challenges in maintaining NERLYNX sales and managing expenses, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, financial stability, and market expansion, Puma is poised for continued growth and success in the biotechnology sector.
Investors should monitor Puma's progress in clinical trials, revenue diversification, and cost management for insights into its future performance.

Puma Biotechnology reports strong revenue, eyes product approvals for growth

Puma Biotechnology's Q2 2024 performance reflects solid revenue generation and strategic investment in innovation.
While facing challenges such as declining new prescriptions and a net loss, the company maintains a focus on cost management.
Opportunities lie in product approvals, revenue growth, and leveraging financial stability for future growth initiatives.
Overall, Puma's financial outlook remains positive, supported by a strong product pipeline and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Puma Biotech (PBYI) delivered earnings and revenue surprises of -373.91% and -13.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Reports Q3 Loss, Misses Revenue Estimates

LOS ANGELES--(BUSINESS WIRE)--On Nov. 4, Puma Biotechnology issued its financial results for the third quarter and nine months ended Sept. 30, 2021.

Puma Biotechnology Reports Third Quarter 2021 Financial Results

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Puma Biotech (PBYI) Report Negative Earnings Next Week? What You Should Know

Cogint

Harpoon Therapeutics Inc

MarketWise

Surrozen

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Sizzling Buy-Rated Biotechs Highlight 5 Top Stocks Under $10

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at 8:00 a.m. EDT on Sept. 28, at the 2021 Cantor Virtual Global Healthcare Conference.

Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at the H.C. Wainwright 23rd Annual Global Investment Conference beginning on Sept. 13.

Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Puma Biotechnology recently reported their Q2 earnings that revealed a beat on EPS and revenue. Unfortunately, the market continues to crush PBYI, which is down ~50% from February.

Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball

Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.

Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2021 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported financial results for the second quarter of 2021 , followed by a conference call on August 5, 2021.

Puma Biotechnology Reports Second Quarter 2021 Financial Results

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Athyrium Capital have entered into an agreement for the issuance of up to $125 million of notes in two tranches.

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital

Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. Knight Therapeutics Inc (OTC: KHTRF) has the exclusive right to commercialize Nerlynx in Canada.

Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results of the global Phase III NALA trial. Knight has the exclusive right to commercialize NERLYNX® in Canada under the terms of a license agreement entered into with Puma Biotechnology, Inc. (NASDAQ: PBYI).

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology received FDA approval to include dose escalation in the NERLYNX label for both early stage and metastatic breast cancer patients.

FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.

Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--The P III ExteNET Trial shows improved outcomes in patients with HER2+ early stage breast cancer who received ≥ 11 months of treatment with neratinib.

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announce the availability of three abstracts on the ASCO Annual Meeting website related to poster presentations on June 4, 2021.

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2021 Results - Earnings Call Transcript

Puma Biotech (PBYI) delivered earnings and revenue surprises of 37.93% and 31.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Q1 Earnings and Revenues Beat Estimates

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released its financial results for the first quarter ended March 31, 2021, after market close on May 6, 2021.

Puma Biotechnology Reports First Quarter 2021 Financial Results

Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

News for Puma Biotechnology Stock (PBYI)